Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.42 |
| ▸ | AKT1S1 | Q96B36 | 3/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.39 |
| ▸ | AKT2 | P31751 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13855514 | 0.85 | RPS6KB1 (0.60) | HTR2CRPS6KB1AKT1S1 | |
| SCHEMBL4064941 | 0.83 | RPS6KB1 (0.55) | HTR2CKITRPS6KB1AXLMKNK1 | |
| SCHEMBL4246878 | 0.82 | AKT2 (0.59) | HTR2CKITRPS6KB1AXLMKNK1 | |
| SCHEMBL4255375 | 0.82 | HTR2C (0.44) | HTR2CKITRPS6KB1AKT1S1ADRB2 | |
| Formic Acid SCHEMBL4255370 | 0.80 | RPS6KB1 (0.54) | HTR2CKITRPS6KB1AKT1S1 | |
| SCHEMBL13229909 | 0.75 | AKT1 (0.69) | AKT1S1AKT2AKT1AKT3 | |
| Hydrochloric Acid SCHEMBL2796785 | 0.74 | AKT1 (0.68) | AKT1S1AKT2AKT1AKT3 | |
| SCHEMBL4247478 | 0.73 | AKT2 (0.59) | HTR2CKITRPS6KB1AKT2AKT1 | |
| SCHEMBL28050474 | 0.73 | HTR2C (0.60) | HTR2CKITAXLMKNK1MKNK2 | |
| SCHEMBL28057522 | 0.71 | HTR2C (0.70) | HTR2CKITAXLMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| WO-2007125320-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | GRK3, GRK4, CDK1 | HTR2C 686/4885KIT 1378/4885RPS6KB1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.